[Our Stories]SML Genetree has published a research paper in world-class journal Biomaterials Research

August 2022


SML Genetree has published a research paper in world-class journal Biomaterials Research

The SML Genetree Nano R&D team announced on August 3rd that SML Genetree has published a research paper in “Biomaterials Research”, an authoritative journal in the field of biomaterials. “Biomaterials Research” is a world-class academic journal that has a JCR (Journal Citation Reports) journal impact factor of 15.863, ranking 3rd among biomedical journals (top 3%) and 2nd among biomaterials journals (5%).

The title of the paper published is “Biocompatible carbonized iodine doped dots for contrast enhanced CT imaging”. Contrast agents are drugs used for CT scans that help to check the state of tissues or blood vessels by artificially adjusting the contrast when making a diagnosis. A contrast agent is used to show a contrast of a target area on an X-ray by using a difference in X-ray absorption in human tissue. The contrast agent currently in use contains iodine or barium, elements capable of absorbing X-rays. Side effects can occur when substances with higher osmotic pressure than plasma are injected into blood vessels. Therefore, nonionic, low osmotic pressure and water-soluble contrast agents are being developed. However, the use of various organic solvents, acids, bases, and catalysts to produce water-soluble contrast agents can increase costs.

In this paper in which Dr. Yo-Han Jeong (team leader) in the SML Genetree Nano R&D Team was named as the first author, the research team increased the iodine content per molecule to achieve an excellent contrast effect and 'carbonized' the material through a simple hydrothermal reaction without catalysts and organic solvents. The paper cites a novel iodine-doped compound for contrast media. This novel chemical has a higher contrast effect (28% improvement) than commercial contrast agents in the contrast material (carbon).

Dr. Yohan Jeong says "By introduction of advanced nanotechnology into molecular diagnosis, it is possible to develop a next-generation POCT (Point-Of-Care Testing) technology and multiple diagnostic kits capable of simultaneous detection. We are conducting follow-up research on room temperature reagent stabilization measures.”